S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Is Gold Really Boring? (Ad)
Housing data weakens, but Toll Brothers stock is still a buy
Teladoc Health gaps down to support level after weak guidance
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Is Gold Really Boring? (Ad)
Housing data weakens, but Toll Brothers stock is still a buy
Teladoc Health gaps down to support level after weak guidance
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Is Gold Really Boring? (Ad)
Housing data weakens, but Toll Brothers stock is still a buy
Teladoc Health gaps down to support level after weak guidance
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Is Gold Really Boring? (Ad)
Housing data weakens, but Toll Brothers stock is still a buy
Teladoc Health gaps down to support level after weak guidance
NASDAQ:IKNA

Ikena Oncology (IKNA) Stock Price, News & Analysis

$1.33
-0.06 (-4.32%)
(As of 02/21/2024 ET)
Today's Range
$1.28
$1.40
50-Day Range
$1.27
$2.26
52-Week Range
$1.02
$7.64
Volume
476,540 shs
Average Volume
448,231 shs
Market Capitalization
$64.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.67

Ikena Oncology MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
702.0% Upside
$10.67 Price Target
Short Interest
Healthy
2.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.63) to ($1.54) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.75 out of 5 stars

Medical Sector

388th out of 932 stocks

Biological Products, Except Diagnostic Industry

62nd out of 160 stocks


IKNA stock logo

About Ikena Oncology Stock (NASDAQ:IKNA)

Ikena Oncology, Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway. It also develops IK-595, designed to trap MEK and RAF for inhibiting RAS signals than existing inhibitors; and IK-175, a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors, including urothelial carcinomas. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

IKNA Stock Price History

IKNA Stock News Headlines

Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Ikena Oncology Inc (IKNA)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Ikena Oncology Inc IKNA
See More Headlines
Receive IKNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ikena Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
2/22/2024
Next Earnings (Estimated)
3/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IKNA
Fax
N/A
Employees
57
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.67
High Stock Price Target
$13.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+702.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-68,760,000.00
Net Margins
-327.46%
Pretax Margin
-491.69%

Debt

Sales & Book Value

Annual Sales
$15.62 million
Book Value
$4.05 per share

Miscellaneous

Free Float
45,387,000
Market Cap
$64.19 million
Optionable
Not Optionable
Beta
0.27
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Mark Manfredi Ph.D. (Age 53)
    President, CEO & Director
    Comp: $803.9k
  • Dr. Jotin Marango M.D. (Age 45)
    Ph.D., CFO & Head of Corporate Development
    Comp: $581.42k
  • Dr. Sergio L. Santillana M.B.A. (Age 61)
    M.D., M.Sc., Chief Medical Officer
    Comp: $632.18k
  • Mr. Bob Lally
    Senior Vice President of Finance & Operations
  • Dr. Michelle Zhang Ph.D.
    Chief Scientific Officer
  • Ms. Samantha Vuksanic
    Head of Human Resources
  • Mr. Jeffrey Ecsedy Ph.D. (Age 54)
    Chief Development Officer
  • Mr. Alexander Constan Ph.D.
    Senior Vice President of Non Clinical Safety & DMPK
  • Mr. Navin Parwani M.S.
    VP & Head of Quality
  • Ms. Sabine Ruppel Ph.D.
    VP & Head of Discovery














IKNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Ikena Oncology stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ikena Oncology in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IKNA shares.
View IKNA analyst ratings
or view top-rated stocks.

What is Ikena Oncology's stock price target for 2024?

4 Wall Street analysts have issued 1-year price objectives for Ikena Oncology's shares. Their IKNA share price targets range from $8.00 to $13.00. On average, they anticipate the company's stock price to reach $10.67 in the next twelve months. This suggests a possible upside of 702.0% from the stock's current price.
View analysts price targets for IKNA
or view top-rated stocks among Wall Street analysts.

How have IKNA shares performed in 2024?

Ikena Oncology's stock was trading at $1.97 at the beginning of 2024. Since then, IKNA stock has decreased by 32.5% and is now trading at $1.33.
View the best growth stocks for 2024 here
.

Are investors shorting Ikena Oncology?

Ikena Oncology saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 559,400 shares, an increase of 30.5% from the January 15th total of 428,700 shares. Based on an average daily trading volume, of 269,100 shares, the short-interest ratio is currently 2.1 days. Approximately 2.0% of the shares of the company are sold short.
View Ikena Oncology's Short Interest
.

When is Ikena Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024.
View our IKNA earnings forecast
.

How were Ikena Oncology's earnings last quarter?

Ikena Oncology, Inc. (NASDAQ:IKNA) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.02. The business earned $3.75 million during the quarter, compared to analysts' expectations of $2.92 million. Ikena Oncology had a negative net margin of 327.46% and a negative trailing twelve-month return on equity of 42.27%.

When did Ikena Oncology IPO?

(IKNA) raised $125 million in an initial public offering (IPO) on Friday, March 26th 2021. The company issued 7,800,000 shares at $15.00-$17.00 per share. Jefferies, Cowen, Credit Suisse and William Blair acted as the underwriters for the IPO.

Who are Ikena Oncology's major shareholders?

Ikena Oncology's stock is owned by a number of institutional and retail investors. Top institutional investors include BVF Inc. IL (9.88%), Blue Owl Capital Holdings LP (4.05%), Vanguard Group Inc. (3.16%), Verition Fund Management LLC (2.74%), Vestal Point Capital LP (0.67%) and Barclays PLC (0.51%). Insiders that own company stock include Jean Francois Formela, Venture Fund Xi LP Atlas and Xiaoyan Michelle Zhang.
View institutional ownership trends
.

How do I buy shares of Ikena Oncology?

Shares of IKNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IKNA) was last updated on 2/22/2024 by MarketBeat.com Staff